Cardiopulmonary dysfunction, including inadequate left ventricular ejection function at baseline, less than % by either echocardiogram or multiple-gated acquisition scan
Left ventricular ejection fraction (LVEF) within  absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within  days prior to study registration (i.e., if the institutional normal is %, subjects LVEF may be as low as % to be eligible for the study)
Left ventricular ejection fraction (LVEF) greater than % on echocardiography or multiple gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) of % or greater, as measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, within  days before the first dose of TAK-
Participant has a left ventricular ejection fraction (LVEF) <% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO);
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>=)  percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans
Screening calculated LVEF of ?% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan
Left ventricular ejection fraction determined by echocardiogram or multiple-gated acquisition scan (MUGA) (cardiac scan) must be % or higher
Left ventricular ejection fraction of % or more at baseline (by echocardiography or multiple-gated acquisition scanning)
Left ventricular ejection fraction (LVEF) >= % as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within  month before starting lymphodepleting chemotherapy
Left ventricular ejection fraction (LVEF) >= % measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Symptomatic congestive heart failure (New York Heart Association III-IV) or documented cardiomyopathy with left ventricular ejection fraction (LVEF) <% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening. MUGA/ ECHO to be performed within  days prior to registration.
Cardiac ejection fraction >= %, no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or multiple-gated acquisition (MUGA), and no clinically significant electrocardiography (ECG) findings
Left ventricular ejection fraction (LVEF) >/=  percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) within  absolute percentage points of institutional standard of normal (-%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within  weeks prior to first study drug administration (ie, if the institutional normal is %, subjects LVEF may be as low as % to be eligible for the study)
Patients must have a shortening fraction >= % or left ventricular ejection fraction >= % measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA)
Left ventricular ejection fraction (LVEF) of lesser than [<]  percent (%) as determined by multiple uptake gated acquisition (MUGA) or echocardiography during screening
Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= % as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= % measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Left ventricular ejection fraction ? % by echocardiogram or multiple gated acquisition scan.
Left ventricular ejection fraction (LVEF) that is at or above the lower institutional limits of normal, as assessed by multiple gated acquisition (MUGA) scan or echocardiogram within the  weeks prior to registration
Left ventricular ejection fraction (LVEF) >= %, preferably by -dimensional (D) echocardiogram (echo), or by multiple gated acquisition scan (MUGA); however, patients with LVEF of between % and % may also be eligible provided that such patients are cleared by a cardiology consultation; in such cases, cardiology will determine whether it is appropriate to perform a cardiac stress test
Patients must have a left ventricular ejection fraction (LVEF) >= % by echocardiogram or multiple gated acquisition (MUGA) scan within  days prior to registration
Abnormal left ventricular ejection fraction (LVEF; <%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA). [Applies to Phase  only; ECHO/MUGA scans are not performed in Phase .]
Left ventricular ejection fraction (LVEF) ?% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Left Ventricular Shortening Fraction (LVSF) ? % confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ? % confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).
Left ventricular ejection fraction (LVEF) < % as determined by Multiple Gated acquisition scan (MUGA) or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).
Left ventricular ejection fraction (LVEF) greater than % on echocardiography or multiple gated acquisition (MUGA) scan.
Patient has a Left Ventricular Ejection Fraction (LVEF) <  % as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening
For participants who will be receiving CHOP: left ventricular ejection fraction (LVEF) <% by multiple-gated acquisition (MUGA) scan or echocardiogram
Baseline Left Ventricular Ejection Fraction (LVEF) >/=  percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)
Left ventricular ejection fraction less than (<) % as defined by multiple-gated acquisition (MUGA)
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=)  percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
Left ventricular ejection fraction (LVEF) >= % as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented =<  days prior to registration
Baseline left ventricular ejection fraction LVEF >= % as evaluated by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) no more than  absolute percentage points below the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within  weeks prior to first study drug administration (i.e., if the institutional normal is %, subject's LVEF may be as low as % to be eligible for the study)
Baseline left ventricular ejection fraction (LVEF) >/=% measured by echocardiogram (ECHO; preferred) or multiple-gated acquisition (MUGA) scans
Patient has a Left Ventricular Ejection Fraction (LVEF) < % as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= % measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Adequate cardiac function, defined as left ventricular ejection fraction ? % as assessed by echocardiogram or multiple uptake gated acquisition scan performed within  days prior to determination of eligibility
Left ventricular ejection fraction (LVEF) at least % by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction within institutional normal limits, as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) % by multiple-gated acquisition (MUGA) scan or echocardiogram
Adequate cardiac function, defined by baseline LVEF greater than % by Multiple Gated Acquisition (MUGA) scan or echocardiogram.
Multiple Gated Acquisition (MUGA) or echocardiogram (ECHO) must demonstrate LVEF >/= %.
Normal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram
Baseline left ventricular ejection fraction (LVEF) less than (<) %, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Left Ventricular Ejection Fraction (LVEF) < % as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO).
Normal left ventricular ejection fraction on screening assessed by transthoracic echocardiogram or multiple gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) at least % by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) < % as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
Normal (greater than %) left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiography
Baseline multiple gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) >= % by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP
Left ventricular ejection fraction (LVEF) at least % by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) be at least >= institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within  weeks prior to first study drug administration
Left ventricular ejection fraction (LVEF) >% on echocardiography or multiple-gate acquisition (MUGA) scan.
Left ventricular ejection fraction (LVEF) < percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within  weeks before receiving the first dose of study drug.
